Overview
Hepatitis D Virus (HDV), also known as delta virus, is a unique pathogen that can only replicate in the presence of Hepatitis B Virus (HBV). It is considered a satellite virus because it depends on HBV for its envelope proteins. HDV infection leads to more severe liver disease than HBV alone, including fulminant hepatitis and accelerated progression to cirrhosis. The virus was first identified in 1977 in patients with severe HBV infections. It is estimated that approximately 5% of HBV carriers worldwide are coinfected with HDV. The virus is primarily transmitted through percutaneous or mucosal exposure to infected blood or body fluids, similar to HBV.
Key Features
HDV has a circular, single-stranded RNA genome, which is the smallest known viral genome infecting humans. Unlike other viruses, HDV does not encode its own envelope proteins but instead uses HBV's surface antigen (HBsAg) to form viral particles. This dependency makes HDV infection impossible without concurrent or prior HBV infection. The virus exhibits high genetic variability, with at least eight genotypes identified. Genotype 1 is the most widespread, while genotypes 2 and 4 are found in East Asia and tend to cause milder disease. HDV is highly pathogenic and can lead to severe liver damage, with mortality rates up to 20% in acute infections.
Application Areas
HDV is primarily studied in virology and hepatology research to understand viral pathogenesis and develop treatments. Current research focuses on the virus's unique replication mechanism, which involves host RNA polymerases. This makes HDV an interesting model for studying RNA editing and virus-host interactions. In clinical practice, HDV testing is crucial for managing HBV-infected patients, particularly those with severe or progressive liver disease. Public health efforts target HDV prevention through HBV vaccination, as HBV immunization effectively prevents HDV infection. Antiviral development for HDV is challenging due to its dependence on HBV and unique replication strategy.
Precautions
Prevention of HDV infection relies entirely on preventing HBV infection, as HDV cannot establish infection without HBV. Universal HBV vaccination is the most effective strategy. For HBV-infected individuals, regular monitoring for HDV coinfection is recommended, especially if liver disease progresses unexpectedly. Healthcare workers should follow standard precautions when handling blood and body fluids. Injection drug users are at particularly high risk and should have access to clean needle programs. For chronic HDV infection, treatment options are limited, but pegylated interferon-alpha may be attempted under specialist supervision.
B2B Procurement Guide
For research institutions needing HDV reagents, ensure suppliers provide proper documentation of viral source and inactivation methods. Diagnostic laboratories should procure FDA-cleared or CE-marked HDV RNA or antibody tests from reputable manufacturers. Consider test sensitivity and specificity, as HDV diagnosis can be challenging due to fluctuating viral loads. When purchasing HBV vaccines for HDV prevention, verify they meet WHO prequalification standards. For antiviral research, source HDV clones from authenticated repositories. Always comply with biosafety regulations when working with HDV materials, typically requiring at least BSL-2 containment.
Related Manufacturers
- 主营：蛋白酶、蜗牛酶、心肌黄酶、人抗丁型肝炎病毒抗体、亮抑肽酶、淀粉酶、乳糖酶、亮抑酶肽、硫代辅酶、细胞溶解酶、果胶酶、肌酸激酶、纤维素酶、枯草杆菌、乙醇脱氢酶、木聚糖酶、氯化溶菌酶、脂氧素、葡球菌酶、羧化辅酶、尿素酶、氯化酵素